医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

TransEnterix Announces Distribution Agreement for Australia and New Zealand for Senhance Surgical Robotic System

2016年11月09日 AM06:30
このエントリーをはてなブックマークに追加


 

RESEARCH TRIANGLE PARK, N.C.

TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that it has expanded distribution of the Senhance™ Surgical Robotic System (the “Senhance”). TransEnterix has partnered with Getz Healthcare to be the exclusive distribution partner for the Senhance in the Australian and New Zealand markets.

“Australia and New Zealand are key markets in the healthcare industry, with leading hospitals and a growing interest in robotic surgery,” said Todd M. Pope, President and CEO at TransEnterix. “Getz Healthcare is an integrated healthcare distributor with a long track record of success in selling and supporting hospital products. We are excited to partner with such a talented and experienced team in this important region.”

“The Senhance will now be a leading product for our medical device business in Australia and New Zealand,” said James Simkins, CEO of Getz Healthcare. “We chose to partner with TransEnterix because of the tremendous value proposition that the Senhance provides to patients and healthcare providers. Hospitals today are seeking a new way to utilize robotics in surgery that allows them to better manage operational costs. The Senhance’s unique features, including haptic force feedback and eye sensing camera control, as well as its attractive economics are providing surgeons an improved solution.”

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the commercialization of the Senhance™ Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The company is also developing the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System has been granted a CE Mark but is not currently available for sale in the United States. For more information, visit the TransEnterix website at www.transenterix.com.

About Getz Healthcare

Getz Healthcare is a leading pan-Asian distributor of medical devices and equipment, with operations in nine countries across the region. Getz Healthcare partners with leading manufacturers and innovators of medical technology – “Medtech companies pathway to Asia Pacific”. The Australia and New Zealand operations of Getz Healthcare (formerly Medtel) were established in 1965 with sales and service offices located across Australia and New Zealand. Getz Healthcare is a member of The Getz Group of Companies, an international marketing and services company, with businesses in a number of industries. The Getz Group was founded in the US in 1852 and established operations in Asia in 1871. The core operations of the group are in the Asia Pacific region with over 150 offices and 12,000 employees. For more information, visit the Getz Healthcare website at www-au.getzhealthcare.com/au.

Forward Looking Statements

This press release includes statements relating to The Senhance™ Surgical Robotic System and the SurgiBot™ System and our current regulatory and commercialization plans for these products. These statements and other statements regarding our future plans and goals constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether hospitals in Australia and New Zealand have a growing interest in robotic surgery and whether our distribution agreement with Getz Healthcare we will be successful in Australia and New Zealand. For a discussion of the risks and uncertainties associated with TransEnterix’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 3, 2016 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161108006144/en/

CONTACT

For TransEnterix, Inc.
Investor Contact:
Mark Klausner,
+1 443-213-0501
invest@transenterix.com
or
Media
Contact:

(For EU) Conrad Harrington, +44 (0)20 3178 8914
(For
US) Hannah Dunning, +1 415-618-8750
TransEnterix-SVC@sardverb.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Vyome Presents on Development of Dual Action Rational Therapeutics (DARTs) to Treat Infections Caused by Antibiotic-Resistant Skin Opportunist Pathogens at Re-Entering Antibacterial Discovery and Development Summit 2016
  • CRISPRライセンシングのニーズに応えるMPEG LAイニシアチブ
  • 世界肺癌大会上呈报ABOUND数据,探索ABRAXANE®用于挑战性患者群体的安全性和有效性
  • Ajinomoto Is Awarded for the Contribution to Reduce Greenhouse Gas through Feed-Use L-Lysine
  • Ancillare宣布任命亚太区副总裁